ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Adult T-Cell Leukemia & Lymphoma Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Published Date: October 2024
|
Report Code: QYRE-Auto-30K8890
Home | Market Reports | Health| Health Conditions| Cancer
Global Adult T Cell Leukemia Lymphoma Treatment Market Size Status and Forecast 2022
BUY CHAPTERS

Adult T-Cell Leukemia & Lymphoma Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-30K8890
Report
October 2024
Pages:91
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Kyowa Kirin
Seattle Genetics Inc
HUYA Bioscience International
Daiichi Sankyo Co Ltd
miRagen Therapeutics, Inc.
Celgene Corporation (Bristol-Myers Squibb)
Novartis
BioCryst Pharmaceuticals

Adult T-Cell Leukemia & Lymphoma Treatment - Market Size

The global market for Adult T-Cell Leukemia & Lymphoma Treatment was estimated to be worth US$ 123.6 million in 2023 and is forecast to a readjusted size of US$ 155.9 million by 2030 with a CAGR of 3.3% during the forecast period 2024-2030

Adult T-Cell Leukemia & Lymphoma Treatment - Market

Adult T-Cell Leukemia & Lymphoma Treatment - Market

Adult T-cell lymphoma/leukemia (ATL) is a rare T-cell lymphoproliferative neoplasm caused by human T-lymphotrophic virus 1. In its more common, aggressive forms, ATL carries one of the poorest prognoses of the non-Hodgkin lymphomas. The disease has clinical subtypes (ie, acute, lymphoma, chronic, and smoldering forms) defined by the presenting features, and therefore, the clinical course can vary. For the smoldering and lower-risk chronic forms, combinations involving antiviral therapies have shown some success. However, in many patients, the more indolent forms will evolve into the more aggressive subtypes. In the more aggressive acute, lymphoma, and higher-risk chronic forms, the literature supports initial treatment with combination chemotherapy followed by allogeneic transplantation as a potentially curative approach.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Adult T-Cell Leukemia & Lymphoma Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Adult T-Cell Leukemia & Lymphoma Treatment by region & country, by Type, and by Application.
The Adult T-Cell Leukemia & Lymphoma Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adult T-Cell Leukemia & Lymphoma Treatment.
Market Segmentation

Scope of Adult T-Cell Leukemia & Lymphoma Treatment - Market Report

Report Metric Details
Report Name Adult T-Cell Leukemia & Lymphoma Treatment - Market
Forecasted market size in 2030 US$ 155.9 million
CAGR 3.3%
Forecasted years 2024 - 2030
Segment by Type:
  • Brentuximab Vedotin
  • HBI-8000
  • Others
Segment by Application
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Daiichi Sankyo Co. Ltd., Seattle Genetics Inc., miRagen Therapeutics Inc., Celgene Corporation (Bristol-Myers Squibb), HUYA Bioscience International, Novartis, BioCryst Pharmaceuticals, Kyowa Kirin
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Adult T-Cell Leukemia & Lymphoma Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Revenue of Adult T-Cell Leukemia & Lymphoma Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Revenue of Adult T-Cell Leukemia & Lymphoma Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

What is the Adult T-Cell Leukemia & Lymphoma Treatment - Market size in 2030?

Ans: The Adult T-Cell Leukemia & Lymphoma Treatment - Market size in 2030 will be US$ 155.9 million.

Who are the main players in the Adult T-Cell Leukemia & Lymphoma Treatment - Market report?

Ans: The main players in the Adult T-Cell Leukemia & Lymphoma Treatment - Market are Daiichi Sankyo Co. Ltd., Seattle Genetics Inc., miRagen Therapeutics Inc., Celgene Corporation (Bristol-Myers Squibb), HUYA Bioscience International, Novartis, BioCryst Pharmaceuticals, Kyowa Kirin

What are the Application segmentation covered in the Adult T-Cell Leukemia & Lymphoma Treatment - Market report?

Ans: The Applications covered in the Adult T-Cell Leukemia & Lymphoma Treatment - Market report are Hospitals, Clinics, Ambulatory Surgical Centers, Others

What are the Type segmentation covered in the Adult T-Cell Leukemia & Lymphoma Treatment - Market report?

Ans: The Types covered in the Adult T-Cell Leukemia & Lymphoma Treatment - Market report are Brentuximab Vedotin, HBI-8000, Others

1 Market Overview
1.1 Adult T-Cell Leukemia & Lymphoma Treatment Product Introduction
1.2 Global Adult T-Cell Leukemia & Lymphoma Treatment Market Size Forecast
1.3 Adult T-Cell Leukemia & Lymphoma Treatment Market Trends & Drivers
1.3.1 Adult T-Cell Leukemia & Lymphoma Treatment Industry Trends
1.3.2 Adult T-Cell Leukemia & Lymphoma Treatment Market Drivers & Opportunity
1.3.3 Adult T-Cell Leukemia & Lymphoma Treatment Market Challenges
1.3.4 Adult T-Cell Leukemia & Lymphoma Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Adult T-Cell Leukemia & Lymphoma Treatment Players Revenue Ranking (2023)
2.2 Global Adult T-Cell Leukemia & Lymphoma Treatment Revenue by Company (2019-2024)
2.3 Key Companies Adult T-Cell Leukemia & Lymphoma Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Adult T-Cell Leukemia & Lymphoma Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Adult T-Cell Leukemia & Lymphoma Treatment
2.6 Adult T-Cell Leukemia & Lymphoma Treatment Market Competitive Analysis
2.6.1 Adult T-Cell Leukemia & Lymphoma Treatment Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Adult T-Cell Leukemia & Lymphoma Treatment Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adult T-Cell Leukemia & Lymphoma Treatment as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Brentuximab Vedotin
3.1.2 HBI-8000
3.1.3 Others
3.2 Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Type
3.2.1 Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Clinics
4.1.3 Ambulatory Surgical Centers
4.1.4 Others
4.2 Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Application
4.2.1 Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Region
5.1.1 Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Region (2019-2024)
5.1.3 Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Region (2025-2030)
5.1.4 Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, 2019-2030
5.2.2 North America Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, 2019-2030
5.3.2 Europe Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, 2019-2030
5.4.2 Asia Pacific Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, 2019-2030
5.5.2 South America Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, 2019-2030
5.6.2 Middle East & Africa Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Adult T-Cell Leukemia & Lymphoma Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Adult T-Cell Leukemia & Lymphoma Treatment Sales Value
6.3 United States
6.3.1 United States Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, 2019-2030
6.3.2 United States Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, 2019-2030
6.4.2 Europe Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, 2019-2030
6.5.2 China Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, 2019-2030
6.6.2 Japan Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, 2019-2030
6.7.2 South Korea Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, 2019-2030
6.9.2 India Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Daiichi Sankyo Co. Ltd.
7.1.1 Daiichi Sankyo Co. Ltd. Profile
7.1.2 Daiichi Sankyo Co. Ltd. Main Business
7.1.3 Daiichi Sankyo Co. Ltd. Adult T-Cell Leukemia & Lymphoma Treatment Products, Services and Solutions
7.1.4 Daiichi Sankyo Co. Ltd. Adult T-Cell Leukemia & Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.1.5 Daiichi Sankyo Co. Ltd. Recent Developments
7.2 Seattle Genetics Inc.
7.2.1 Seattle Genetics Inc. Profile
7.2.2 Seattle Genetics Inc. Main Business
7.2.3 Seattle Genetics Inc. Adult T-Cell Leukemia & Lymphoma Treatment Products, Services and Solutions
7.2.4 Seattle Genetics Inc. Adult T-Cell Leukemia & Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.2.5 Seattle Genetics Inc. Recent Developments
7.3 miRagen Therapeutics Inc.
7.3.1 miRagen Therapeutics Inc. Profile
7.3.2 miRagen Therapeutics Inc. Main Business
7.3.3 miRagen Therapeutics Inc. Adult T-Cell Leukemia & Lymphoma Treatment Products, Services and Solutions
7.3.4 miRagen Therapeutics Inc. Adult T-Cell Leukemia & Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.3.5 Celgene Corporation (Bristol-Myers Squibb) Recent Developments
7.4 Celgene Corporation (Bristol-Myers Squibb)
7.4.1 Celgene Corporation (Bristol-Myers Squibb) Profile
7.4.2 Celgene Corporation (Bristol-Myers Squibb) Main Business
7.4.3 Celgene Corporation (Bristol-Myers Squibb) Adult T-Cell Leukemia & Lymphoma Treatment Products, Services and Solutions
7.4.4 Celgene Corporation (Bristol-Myers Squibb) Adult T-Cell Leukemia & Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.4.5 Celgene Corporation (Bristol-Myers Squibb) Recent Developments
7.5 HUYA Bioscience International
7.5.1 HUYA Bioscience International Profile
7.5.2 HUYA Bioscience International Main Business
7.5.3 HUYA Bioscience International Adult T-Cell Leukemia & Lymphoma Treatment Products, Services and Solutions
7.5.4 HUYA Bioscience International Adult T-Cell Leukemia & Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.5.5 HUYA Bioscience International Recent Developments
7.6 Novartis
7.6.1 Novartis Profile
7.6.2 Novartis Main Business
7.6.3 Novartis Adult T-Cell Leukemia & Lymphoma Treatment Products, Services and Solutions
7.6.4 Novartis Adult T-Cell Leukemia & Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.6.5 Novartis Recent Developments
7.7 BioCryst Pharmaceuticals
7.7.1 BioCryst Pharmaceuticals Profile
7.7.2 BioCryst Pharmaceuticals Main Business
7.7.3 BioCryst Pharmaceuticals Adult T-Cell Leukemia & Lymphoma Treatment Products, Services and Solutions
7.7.4 BioCryst Pharmaceuticals Adult T-Cell Leukemia & Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.7.5 BioCryst Pharmaceuticals Recent Developments
7.8 Kyowa Kirin
7.8.1 Kyowa Kirin Profile
7.8.2 Kyowa Kirin Main Business
7.8.3 Kyowa Kirin Adult T-Cell Leukemia & Lymphoma Treatment Products, Services and Solutions
7.8.4 Kyowa Kirin Adult T-Cell Leukemia & Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.8.5 Kyowa Kirin Recent Developments
8 Industry Chain Analysis
8.1 Adult T-Cell Leukemia & Lymphoma Treatment Industrial Chain
8.2 Adult T-Cell Leukemia & Lymphoma Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Adult T-Cell Leukemia & Lymphoma Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Adult T-Cell Leukemia & Lymphoma Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
FEATURED COMPANIES
Kyowa Kirin
Seattle Genetics Inc
HUYA Bioscience International
Daiichi Sankyo Co Ltd
miRagen Therapeutics, Inc.
Celgene Corporation (Bristol-Myers Squibb)
Novartis
BioCryst Pharmaceuticals
List of Tables
    Table 1. Adult T-Cell Leukemia & Lymphoma Treatment Market Trends
    Table 2. Adult T-Cell Leukemia & Lymphoma Treatment Market Drivers & Opportunity
    Table 3. Adult T-Cell Leukemia & Lymphoma Treatment Market Challenges
    Table 4. Adult T-Cell Leukemia & Lymphoma Treatment Market Restraints
    Table 5. Global Adult T-Cell Leukemia & Lymphoma Treatment Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Adult T-Cell Leukemia & Lymphoma Treatment Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Adult T-Cell Leukemia & Lymphoma Treatment Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Adult T-Cell Leukemia & Lymphoma Treatment Product Type
    Table 9. Key Companies Time to Begin Mass Production of Adult T-Cell Leukemia & Lymphoma Treatment
    Table 10. Global Adult T-Cell Leukemia & Lymphoma Treatment Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adult T-Cell Leukemia & Lymphoma Treatment as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Region (2019-2024) & (%)
    Table 27. Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Adult T-Cell Leukemia & Lymphoma Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, (2025-2030) & (US$ Million)
    Table 31. Daiichi Sankyo Co. Ltd. Basic Information List
    Table 32. Daiichi Sankyo Co. Ltd. Description and Business Overview
    Table 33. Daiichi Sankyo Co. Ltd. Adult T-Cell Leukemia & Lymphoma Treatment Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Adult T-Cell Leukemia & Lymphoma Treatment Business of Daiichi Sankyo Co. Ltd. (2019-2024)
    Table 35. Daiichi Sankyo Co. Ltd. Recent Developments
    Table 36. Seattle Genetics Inc. Basic Information List
    Table 37. Seattle Genetics Inc. Description and Business Overview
    Table 38. Seattle Genetics Inc. Adult T-Cell Leukemia & Lymphoma Treatment Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Adult T-Cell Leukemia & Lymphoma Treatment Business of Seattle Genetics Inc. (2019-2024)
    Table 40. Seattle Genetics Inc. Recent Developments
    Table 41. miRagen Therapeutics Inc. Basic Information List
    Table 42. miRagen Therapeutics Inc. Description and Business Overview
    Table 43. miRagen Therapeutics Inc. Adult T-Cell Leukemia & Lymphoma Treatment Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Adult T-Cell Leukemia & Lymphoma Treatment Business of miRagen Therapeutics Inc. (2019-2024)
    Table 45. miRagen Therapeutics Inc. Recent Developments
    Table 46. Celgene Corporation (Bristol-Myers Squibb) Basic Information List
    Table 47. Celgene Corporation (Bristol-Myers Squibb) Description and Business Overview
    Table 48. Celgene Corporation (Bristol-Myers Squibb) Adult T-Cell Leukemia & Lymphoma Treatment Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Adult T-Cell Leukemia & Lymphoma Treatment Business of Celgene Corporation (Bristol-Myers Squibb) (2019-2024)
    Table 50. Celgene Corporation (Bristol-Myers Squibb) Recent Developments
    Table 51. HUYA Bioscience International Basic Information List
    Table 52. HUYA Bioscience International Description and Business Overview
    Table 53. HUYA Bioscience International Adult T-Cell Leukemia & Lymphoma Treatment Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Adult T-Cell Leukemia & Lymphoma Treatment Business of HUYA Bioscience International (2019-2024)
    Table 55. HUYA Bioscience International Recent Developments
    Table 56. Novartis Basic Information List
    Table 57. Novartis Description and Business Overview
    Table 58. Novartis Adult T-Cell Leukemia & Lymphoma Treatment Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Adult T-Cell Leukemia & Lymphoma Treatment Business of Novartis (2019-2024)
    Table 60. Novartis Recent Developments
    Table 61. BioCryst Pharmaceuticals Basic Information List
    Table 62. BioCryst Pharmaceuticals Description and Business Overview
    Table 63. BioCryst Pharmaceuticals Adult T-Cell Leukemia & Lymphoma Treatment Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Adult T-Cell Leukemia & Lymphoma Treatment Business of BioCryst Pharmaceuticals (2019-2024)
    Table 65. BioCryst Pharmaceuticals Recent Developments
    Table 66. Kyowa Kirin Basic Information List
    Table 67. Kyowa Kirin Description and Business Overview
    Table 68. Kyowa Kirin Adult T-Cell Leukemia & Lymphoma Treatment Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Adult T-Cell Leukemia & Lymphoma Treatment Business of Kyowa Kirin (2019-2024)
    Table 70. Kyowa Kirin Recent Developments
    Table 71. Key Raw Materials Lists
    Table 72. Raw Materials Key Suppliers Lists
    Table 73. Adult T-Cell Leukemia & Lymphoma Treatment Downstream Customers
    Table 74. Adult T-Cell Leukemia & Lymphoma Treatment Distributors List
    Table 75. Research Programs/Design for This Report
    Table 76. Key Data Information from Secondary Sources
    Table 77. Key Data Information from Primary Sources
    Table 78. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Adult T-Cell Leukemia & Lymphoma Treatment Product Picture
    Figure 2. Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value (2019-2030) & (US$ Million)
    Figure 4. Adult T-Cell Leukemia & Lymphoma Treatment Report Years Considered
    Figure 5. Global Adult T-Cell Leukemia & Lymphoma Treatment Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Adult T-Cell Leukemia & Lymphoma Treatment Revenue in 2023
    Figure 7. Adult T-Cell Leukemia & Lymphoma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Brentuximab Vedotin Picture
    Figure 9. HBI-8000 Picture
    Figure 10. Others Picture
    Figure 11. Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 12. Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value Market Share by Type, 2023 & 2030
    Figure 13. Product Picture of Hospitals
    Figure 14. Product Picture of Clinics
    Figure 15. Product Picture of Ambulatory Surgical Centers
    Figure 16. Product Picture of Others
    Figure 17. Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 18. Global Adult T-Cell Leukemia & Lymphoma Treatment Sales Value Market Share by Application, 2023 & 2030
    Figure 19. North America Adult T-Cell Leukemia & Lymphoma Treatment Sales Value (2019-2030) & (US$ Million)
    Figure 20. North America Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
    Figure 21. Europe Adult T-Cell Leukemia & Lymphoma Treatment Sales Value (2019-2030) & (US$ Million)
    Figure 22. Europe Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
    Figure 23. Asia Pacific Adult T-Cell Leukemia & Lymphoma Treatment Sales Value (2019-2030) & (US$ Million)
    Figure 24. Asia Pacific Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
    Figure 25. South America Adult T-Cell Leukemia & Lymphoma Treatment Sales Value (2019-2030) & (US$ Million)
    Figure 26. South America Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
    Figure 27. Middle East & Africa Adult T-Cell Leukemia & Lymphoma Treatment Sales Value (2019-2030) & (US$ Million)
    Figure 28. Middle East & Africa Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
    Figure 29. Key Countries/Regions Adult T-Cell Leukemia & Lymphoma Treatment Sales Value (%), (2019-2030)
    Figure 30. United States Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 31. United States Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 32. United States Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 33. Europe Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 34. Europe Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 35. Europe Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 36. China Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 37. China Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 38. China Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 39. Japan Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 40. Japan Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 41. Japan Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 42. South Korea Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 43. South Korea Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 44. South Korea Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 45. Southeast Asia Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 46. Southeast Asia Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 47. Southeast Asia Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 48. India Adult T-Cell Leukemia & Lymphoma Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 49. India Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 50. India Adult T-Cell Leukemia & Lymphoma Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 51. Adult T-Cell Leukemia & Lymphoma Treatment Industrial Chain
    Figure 52. Adult T-Cell Leukemia & Lymphoma Treatment Manufacturing Cost Structure
    Figure 53. Channels of Distribution (Direct Sales, and Distribution)
    Figure 54. Bottom-up and Top-down Approaches for This Report
    Figure 55. Data Triangulation
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Immunotherapy Drugs for Neuroblastoma - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-39R14639
Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Cancer Early Detection and Diagnosis - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-37I14671
Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Global One-Stop Radiotherapy Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-33G18542
Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Immunotherapy for Neuroblastoma - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-1A14903
Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions